


CLAIMS

What we claim is:

1. A compound of Formula (I):



(I)

wherein:

W and Y are independently a straight or branched chain C₁₋₅ alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C₁₋₅ alkylene group is optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl, C₁₋₄ haloalkyl or C₁₋₄ alkoxy;

X is -NR₃C(O)-, -C(O)NR₃, -NR₃S(O)₂-, -S(O)₂NR₃-, -NR₃C(O)NR₄-, -NR₃C(O)O-, -OC(O)NR₃-, -NR₃-, -C(O)-, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or -S(O)₂-;

R₃ and R₄ are independently H, C₁₋₄ alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

R₁ is H, hydroxyl, halogen, C₁₋₄ alkyl or C₁₋₄ haloalkyl;

R₂ is H or C₁₋₈ alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof; provided that:

i) when both R_1 and R_2 are H then $-[W]_n-X-[Y]_m-Z$ together is not CO_2H , $C(O)-C_6H_4-p-O-C_8H_{17}$, OCH_2CH_3 , OH , $CH_2CH_2CH_2CH_2CO_2H$, $CH_2CH_2CH_2CO_2H$, CH_2CO_2H and $CH_2CH_2CO_2H$;

ii) when R_1 is CH_3 and R_2 is H then $-[W]_n-X-[Y]_m-Z$ together is not CH_2CO_2H , $C(O)CH=CH C_6H_5$, $C(O)C_6H_4-p-OCH_3$, CO_2H , $C(O)CH_3$, $C(O)C_6H_4-o-CH_3$, $C(O)C_6H_4-o-Br$, $C(O)C_6H_4-o-Cl$, and $C(O)C_6H_5$;

iii) when R_1 is Br and R_2 is H then $-[W]_n-X-[Y]_m-Z$ together is not CO_2H ;

iv) when R_1 is OH and R_2 is H then $-[W]_n-X-[Y]_m-Z$ together is not CO_2H ;

v) when R_1 is H and R_2 is CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not 2,6-dichloro-4-trifluoromethylphenoxy, $C(O)NH-C_6H_4-p-OCH_2CH_3$, $NHC(O)CH(CH_3)_2$, SCH_3 , $C(O)-C_6H_4-p-O-C_8H_{17}$, SCH_2CH_3 , $C(O)NHC_6H_5$, $CH(OCH_3)_2$, $CH_2OC(O)CH_3$, CO_2H , CO_2CH_3 , $C(O)C_6H_4-p-NO_2$, $C(O)C_6H_5$, $CH_2CH_2CO_2CH_3$, $CH_2CH_2CH_2CH_2CO_2CH_3$, $CH_2CH_2CH_2CO_2CH_3$ and $CH_2CO_2CH_3$;

vi) when R_1 is OH and R_2 is CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH_2OCH_2C_6H_5$, $CH_2OCH(CH_3)_2$ and CH_2OH ;

vii) when R_2 is CH_3 then:

R_1 is not CH_3 and $-[W]_n-X-[Y]_m-Z$ together is not 2,6-dichloro-4-trifluoromethylphenoxy;

R_1 is not I and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2C(CH_3)_3$;

R_1 is not $C(CH_3)_3$ and $-[W]_n-X-[Y]_m-Z$ together is not formyl;

R_1 is not Br and $-[W]_n-X-[Y]_m-Z$ together is not CO_2CH_3 ;

and
 R_1 is not $CH_2CH_2CH_2CH_3$ and $-[W]_n-X-[Y]_m-Z$ together is not formyl;

viii) when R_1 is H and R_2 is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH_2SCH_2CH_3$, $OCH_2CH_2CH=CH_2$, $CH_2CH_2CH_2OH$, CH_2CH_2CHO , $CO_2CH_2CH_3$, OCH_3 , $C(O)CH_2Br$, $CO_2C_8H_{17}$, formyl, OH , $CH_2N(CH_2CH_2Cl)_2$, $CH(CH_3)OC(O)CH_3$, CH_2OH , $CH_2OC(O)CH_3$, $C(O)CH_3$, $C(O)C_6H_5$ and $C(O)NHCH_2CO_2CH_2CH_3$.

ix) when R_1 is CH_3 and R_2 is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH(OH)C_6H_4-p-N(CH_3)_2$, $C(O)CH_2C(O)CH_3$, $CO_2CH_2C_6H_5$, CO_2CH_3 , $C(O)CH_2CH_2CH_3$, $C(O)CH_3$, $C(O)C_6H_4-p-OCH_3$, $C(O)C_6H_4-o-Br$, $C(O)C_6H_4-p-Cl$, $C(O)C_6H_4-o-Cl$, $C(O)CH_2C_6H_5$ and $C(O)C_6H_5$;

x) when R_2 is CH_2CH_3 then:

R_1 is not I and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2CH_2CH_3$;

R_1 is not CF_3 and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2CH_2CH_3$; and

R_1 is not Br and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2CH_2CH_3$;

xi) when R_1 is OH and R_2 is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $C(O)C_6H_5$, $C(O)NH_2$ and $CO_2CH_2CH_3$;

xii) when R_1 is H and R_2 is $C(CH_3)_3$ then $-[W]_n-X-[Y]_m-Z$ together is not $CO_2C(CH_3)_3$, $C(O)NHC(O)CH_3$ and $C(O)NH_2$;

xiii) when R_1 is OH and R_2 is $CH_2CH_2CH_2CH_3$ then $-[W]_n-X-[Y]_m-Z$ together is not $C(O)C_6H_5$; and

xiv) when X is $-NR_3-$ then "n" is 1.

2. The compound according to claim 1 wherein "n" is 0.

3. The compound according to claim 1 wherein "n" is 1.

4. The compound according to any one of claims 1 to 3 wherein "m" is 0.

5. The compound according to any one of claims 1 to 3 wherein "m" is 1.

6. The compound according to any one of claims 1, 3, 4 and 5 wherein W is the straight or branched C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

7. The compound according to claim 6 wherein W is $-CH_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

8. The compound according to claim 7 wherein W is $-CH(CH_3)-$ optionally substituted with halogen, hydroxyl or C_{1-4} alkoxy.

9. The compound according to claim 7 wherein W is $-C(CH_3)_2-$.

10. The compound according to claim 6 wherein W is $-CH_2CH_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

11. The compound according to claim 10 wherein W is $-\text{CH}(\text{CH}_3)\text{CH}_2-$ or $-\text{CH}_2\text{CH}(\text{CH}_3)-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 5 12. The compound according to claim 10 wherein W is $-\text{C}(\text{CH}_3)_2\text{CH}_2-$ or $-\text{CH}_2\text{C}(\text{CH}_3)_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 10 13. The compound according to claim 10 wherein W is $-\text{CH}(\text{OCH}_3)\text{CH}_2-$ or $-\text{CH}_2\text{CH}(\text{OCH}_3)-$ optionally substituted with halogen, hydroxyl or C_{1-4} alkyl.
14. The compound according to claim 6 wherein W is $-\text{CH}_2\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 15 15. The compound according to claim 6 wherein W is $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
16. The compound according to claim 6 wherein W is $-\text{CH}=\text{CH}-$ optionally substituted with C_{1-4} alkyl or C_{1-4} alkoxy.
- 20 17. The compound according to claim 6 wherein W is $-\text{C}\equiv\text{C}-$.
18. The compound according to claim 6 wherein W is $-\text{C}(\text{O})-$.
- 25 19. The compound according to claim 6 wherein W is $-\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
20. The compound according to claim 19 wherein W is $-\text{CH}(\text{CH}_3)\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}(\text{CH}_3)-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 30 21. The compound according to claim 19 wherein W is $-\text{C}(\text{CH}_3)_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{C}(\text{CH}_3)_2-$.
- 35 22. The compound according to claim 6 wherein W is $-\text{CH}_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

23. The compound according to claim 22 wherein W is $-\text{C}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{C}(\text{CH}_3)_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
24. The compound according to claim 6 wherein W is $-\text{CH}_2\text{C}(\text{O})\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
25. The compound according to claim 6 wherein W is $-\text{CH}_2\text{CH}_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
26. The compound according to claim 6 wherein W is $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
27. The compound according to claim 6 wherein W is $-\text{CH}_2\text{CH}_2\text{C}(\text{O})\text{CH}_2-$ or $-\text{CH}_2\text{C}(\text{O})\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
28. The compound according to claim 6 wherein W is $-\text{CH}=\text{CHC}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}=\text{CH}-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
29. The compound according to claim 6 wherein W is $-\text{C}(\text{CH}_3)=\text{CHC}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}=\text{C}(\text{CH}_3)-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
30. The compound according to any one of claims 1, 2, 3 and 5 to 28 wherein Y is the straight or branched chain C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
31. The compound according to claim 30 wherein Y is $-\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
32. The compound according to claim 31 wherein Y is $-\text{CH}(\text{CH}_3)-$ optionally substituted

with halogen, hydroxyl or C₁₋₄ alkoxy.

33. The compound according to claim 31 wherein Y is -C(CH₃)₂-.
- 5 34. The compound according to claim 30 wherein Y is -CH₂CH₂- optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.
- 10 35. The compound according to claim 34 wherein Y is -CH(CH₃)CH₂- or -CH₂CH(CH₃)- optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.
- 15 36. The compound according to claim 34 wherein Y is -C(CH₃)₂CH₂- or -CH₂C(CH₃)₂- optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.
- 20 37. The compound according to claim 34 wherein Y is -CH(OCH₃)CH₂- or -CH₂CH(OCH₃)- optionally substituted with halogen, hydroxyl or C₁₋₄ alkyl.
38. The compound according to claim 30 wherein Y is -CH₂CH₂CH₂- optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.
39. The compound according to claim 30 wherein Y is -CH₂CH₂CH₂CH₂- optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.
- 25 40. The compound according to claim 30 wherein Y is -CH=CH- optionally substituted with C₁₋₄ alkyl or C₁₋₄ alkoxy.
41. The compound according to claim 30 wherein Y is -C≡C-.
- 30 42. The compound according to claim 30 wherein Y is -C≡CCH₂- or -CH₂C≡C- optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.
43. The compound according to claim 30 wherein Y is -C(O)-.
- 35 44. The compound according to claim 30 wherein Y is -CH₂C(O)- or -C(O)CH₂- optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.

45. The compound according to claim 44 wherein Y is $-\text{CH}(\text{CH}_3)\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}(\text{CH}_3)-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 5 46. The compound according to claim 44 wherein Y is $-\text{C}(\text{CH}_3)_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{C}(\text{CH}_3)_2-$.
- 10 47. The compound according to claim 30 wherein Y is $-\text{CH}_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 15 48. The compound according to claim 47 wherein Y is $-\text{C}(\text{CH}_3)_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{C}(\text{CH}_3)_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 20 49. The compound according to claim 30 wherein Y is $-\text{CH}_2\text{C}(\text{O})\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 25 50. The compound according to claim 30 wherein Y is $-\text{CH}_2\text{CH}_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 30 51. The compound according to claim 30 wherein Y is $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
- 35 52. The compound according to claim 30 wherein Y is $-\text{CH}_2\text{CH}_2\text{C}(\text{O})\text{CH}_2-$ or $-\text{CH}_2\text{C}(\text{O})\text{CH}_2\text{CH}_2-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
53. The compound according to claim 30 wherein Y is $-\text{CH}=\text{CHC}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}=\text{CH}-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.
54. The compound according to claim 30 wherein Y is $-\text{C}(\text{CH}_3)=\text{CHC}(\text{O})-$ or $-\text{C}(\text{O})\text{CH}=\text{C}(\text{CH}_3)-$ optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

55. The compound according to any one of claims 1 to 54 wherein X is $\text{-NR}_3\text{C(O)-}$.

56. The compound according to any one of claims 1 to 54 wherein X is $\text{-C(O)NR}_3\text{-}$.

57. The compound according to any one of claims 1 to 54 wherein X is $\text{-NR}_3\text{S(O)}_2\text{-}$.

58. The compound according to any one of claims 1 to 54 wherein X is $\text{-S(O)}_2\text{NR}_3\text{-}$.

59. The compound according to any one of claims 1 to 54 wherein X is $\text{-NR}_3\text{C(O)NR}_4\text{-}$.

60. The compound according to any one of claims 1 to 54 wherein X is $\text{-NR}_3\text{C(O)O-}$.

61. The compound according to any one of claims 1 to 54 wherein X is $\text{-OC(O)NR}_3\text{-}$.

62. The compound according to any one of claims 1 to 54 wherein X is $\text{-NR}_3\text{-}$.

63. The compound according to any one of claims 55 to 62 wherein R_3 is H or CH_3 .

64. The compound according to claim 59 wherein R_4 is H or CH_3 .

65. The compound according to any one of claims 1 to 54 wherein X is -C(O)- .

66. The compound according to any one of claims 1 to 54 wherein X is -CH(OH)- .

67. The compound according to any one of claims 1 to 54 wherein X is -C(NH)- .

68. The compound according to any one of claims 1 to 54 wherein X is -O- .


69. The compound according to any one of claims 1 to 54 wherein X is -S- .

70. The compound according to any one of claims 1 to 54 wherein X is -S(O)- .

71. The compound according to any one of claims 1 to 54 wherein X is $\text{-S(O)}_2\text{-}$.

72. The compound according to any one of claims 1 to 71 wherein Z is H.
73. The compound according to any one of claims 1 to 71 wherein Z is halogen.
74. The compound according to any one of claims 1 to 71 wherein Z is phenyl.
75. The compound according to claim 74 wherein the phenyl is optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, C₁₋₄ haloalkyl, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl.
76. The compound according to claim 75 wherein the phenyl is optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, -CF₃, -NHCH₃, -N(CH₃)₂, -CH₃, -CH₂CH₃, -OCH₃ and -OCF₃.
77. The compound according to any one of claims 1 to 71 wherein Z is heteroaryl.
78. The compound according to claim 77 wherein the heteroaryl is optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, C₁₋₄ haloalkyl, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl.
79. The compound according to claim 78 wherein the phenyl is optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, -CF₃, -NHCH₃, -N(CH₃)₂, -CH₃, -CH₂CH₃, -OCH₃ and -OCF₃.
80. The compound according to any one of claims 1 to 79 wherein R₁ is H.
81. The compound according to any one of claims 1 to 79 wherein R₁ is hydroxyl.
82. The compound according to any one of claims 1 to 78 wherein R₁ is halogen.
83. The compound according to any one of claims 1 to 78 wherein R₁ is C₁₋₄ alkyl.

84. The compound according to any one of claims 1 to 78 wherein R_1 is C_{1-4} haloalkyl.
85. The compound according to any one of claims 1 to 84 wherein R_2 is H.
- 5 86. The compound according to any one of claims 1 to 84 wherein R_2 is C_{1-8} alkyl.
87. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with at least one compound according to Formula (I):



10 wherein:

W and Y are independently a straight or branched chain C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{1-4} alkoxy;

15 X is $-NR_3C(O)-$, $-C(O)NR_3$, $-NR_3S(O)_2-$, $-S(O)_2NR_3-$, $-NR_3C(O)NR_4-$, $-NR_3C(O)O-$, $-OC(O)NR_3-$, $-NR_3-$, $-C(O)-$, $-CH(OH)-$, $-C(NH)-$, $-O-$, $-S-$, $-S(O)-$ or $-S(O)_2-$;

20 R_3 and R_4 are independently H, C_{1-4} alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

25 Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

30 R_1 is H, hydroxyl, halogen, C_{1-4} alkyl or C_{1-4} haloalkyl;

R_2 is H or C_{1-8} alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that when X is $-NR_3-$ then "n" is 1.

5

88. The pharmaceutical composition according to claim 87 further comprising one or more agents selected from the group consisting of α -glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione.

10

89. The pharmaceutical composition according to claim 88 wherein the agent is a α -glucosidase inhibitor.

15

90. The pharmaceutical composition according to claim 89 wherein the α -glucosidase inhibitor is acarbose, voglibose or miglitol.

91. The pharmaceutical composition according to claim 90 wherein the α -glucosidase inhibitor is voglibose.

20

92. The pharmaceutical composition according to claim 88 wherein the agent is an aldose reductase inhibitor.

25

93. The pharmaceutical composition according to claim 92 wherein the aldose reductase inhibitor is tolurestat; epalrestat; imirestat; zenarestat; zopolrestat; or sorbinil.

94. The pharmaceutical composition according to claim 88 wherein the agent is a biguanide.

30

95. The pharmaceutical composition according to claim 94 wherein the biguanide is phenformin, metformin or buformin.

96. The pharmaceutical composition according to claim 95 wherein the biguanide is metformin.

35

97. The pharmaceutical composition according to claim 88 wherein the agent is a HMG-

CoA reductase inhibitor.

- 5 98. The pharmaceutical composition according to claim 97 wherein the HMG-CoA reductase inhibitor is rosuvastatin, pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin or cerivastatin.
- 10 99. The pharmaceutical composition according to claim 88 wherein the agent is a fibrate.
100. The pharmaceutical composition according to claim 99 wherein the fibrate is bezafibrate, beclobrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibric acid, etofibrate, fenofibrate, gemfibrozil, nicofibrate, pirifibrate, ronifibrate, simfibrate, or theofibrate.
- 15 101. The pharmaceutical composition according to claim 88 wherein the agent is an angiotensin converting enzyme inhibitor.
- 20 102. The pharmaceutical composition according to claim 101 wherein the angiotensin converting enzyme inhibitor is captopril, enalapril, alacepril, delapril; ramipril, lisinopril, imidapril, benazepril, ceronapril, cilazapril, enalaprilat, fosinopril, moxeltopril, perindopril, quinapril, spirapril, temocapril or trandolapril.
- 25 103. The pharmaceutical composition according to claim 88 wherein the agent is an insulin secretion enhancer.
- 30 104. The pharmaceutical composition according to claim 103 wherein the insulin secretion enhancer is tolbutamide; chlorpropamide; tolazamide; acetohexamide; glycopyramide; glibenclamide; gliclazide; 1-butyl-3-metanilylurea; carbutamide; glibonuride; glipizide; gliquidone; glisoxepid; glybuthiazole; glibuzole; glyhexamide; glymidine; glypinamide; phenbutamide; tolcyclamide, glimepiride, nateglinide, or mitiglinide.
- 35 105. The pharmaceutical composition according to claim 88 wherein the agent is a thiazolidinedione.
106. The pharmaceutical composition according to claim 105 wherein the thiazolidinedione is rosiglitazone or pioglitazone.

107. The pharmaceutical composition according to claim 106 wherein the thiazolidinedione is rosiglitazone.
108. The compound according to any one of claims 1 to 86 for use in a method of treatment of the human or animal body by therapy.
109. The compound according to any one of claims 1 to 86 for use in a method of prophylaxis or treatment of a metabolic-related disorder of the human or animal body by therapy.
110. A method for prophylaxis or treatment of a metabolic-related disorder in an individual in need of said prophylaxis or treatment comprising administering to the individual a therapeutically effective amount of a compound according to any one of claims 1 to 86 or a pharmaceutical composition according to any one of claims 87 to 107.
111. A method of modulating a RUP25 receptor in an individual comprising contacting the receptor with a compound according to any one of claims 1 to 86.
112. The method of modulating the RUP25 receptor according to claim 111 wherein the compound is an agonist.
113. The method of modulating the RUP25 receptor according to claim 111 or 112 wherein the modulation of the RUP25 receptor is for prophylaxis or treatment of a metabolic-related disorder in an individual in need of said prophylaxis or treatment.
114. The method according to claim 110 or 113 wherein the metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.
115. The method according to claim 114 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
116. The method according to claim 115 wherein the metabolic-related disorder is dyslipidemia.

117. The method according to claim 115 wherein the metabolic-related disorder is atherosclerosis.
- 5 118. The method according to claim 115 wherein the metabolic-related disorder is coronary heart disease.
119. The method according to claim 115 wherein the metabolic-related disorder is insulin resistance.
- 10 120. The method according to claim 115 wherein the metabolic-related disorder is type 2 diabetes.
- 15 121. Use of a compound according to any one of claims 1 to 86 for production of a medicament for use in prophylaxis or treatment of a metabolic-related disorder.
- 20 122. The use according to claim 121 further comprising one or more agents selected from the group consisting of α -glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione.
123. The use according to claim 122 wherein the agent is a α -glucosidase inhibitor.
- 25 124. The use according to claim 123 wherein the α -glucosidase inhibitor is acarbose, voglibose or miglitol.
125. The use according to claim 124 wherein the α -glucosidase inhibitor is voglibose.
- 30 126. The use according to claim 122 wherein the agent is an aldose reductase inhibitor.
127. The use according to claim 126 wherein the aldose reductase inhibitor is tolurestat; epalrestat; imirestat; zenarestat; zopolrestat; or sorbinil.
- 35 128. The use according to claim 122 wherein the agent is a biguanide.

129. The use according to claim 128 wherein the biguanide is phenformin, metformin or buformin.
130. The use according to claim 129 wherein the biguanide is metformin.
131. The use according to claim 122 wherein the agent is a HMG-CoA reductase inhibitor.
132. The use according to claim 131 wherein the HMG-CoA reductase inhibitor is rosuvastatin, pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin or cerivastatin.
133. The use according to claim 122 wherein the agent is a fibrate.
134. The use according to claim 133 wherein the fibrate is bezafibrate, beclobrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibric acid, etofibrate, fenofibrate, gemfibrozil, nicofibrate, pirifibrate, ronifibrate, simfibrate, or theofibrate.
135. The use according to claim 122 wherein the agent is an angiotensin converting enzyme inhibitor.
136. The use according to claim 135 wherein the angiotensin converting enzyme inhibitor is captopril, enalapril, alacepril, delapril; ramipril, lisinopril, imidapril, benazepril, ceronapril, cilazapril, enalaprilat, fosinopril, moveltopril, perindopril, quinapril, spirapril, temocapril or trandolapril.
137. The use according to claim 122 wherein the agent is an insulin secretion enhancer.
138. The use according to claim 137 wherein the insulin secretion enhancer is tolbutamide; chlorpropamide; tolazamide; acetohexamide; glycopyramide; glibenclamide; gliclazide; 1-butyl-3-metanilylurea; carbutamide; glibonuride; glipizide; gliquidone; glisoxepid; glybuthiazole; glibuzole; glyhexamide; glymidine; glypinamide; phenbutamide; tolcyclamide, glimepiride, nateglinide, or mitiglinide.
139. The use according to claim 122 wherein the agent is a thiazolidinedione.
140. The use according to claim 139 wherein the thiazolidinedione is rosiglitazone or pioglitazone.

141. The use according to claim 140 wherein the thiazolidinedione is rosiglitazone.

5 142. The use according to any one of claims 121 to 141 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

10 143. The use according to claim 142 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

15 144. The use according to claim 143 wherein the metabolic-related disorder is dyslipidemia.

145. The use according to claim 143 wherein the metabolic-related disorder is atherosclerosis.

20 146. The use according to claim 143 wherein the metabolic-related disorder is coronary heart disease.

147. The use according to claim 143 wherein the metabolic-related disorder is insulin resistance.

25 148. The use according to claim 143 wherein the metabolic-related disorder is type 2 diabetes.

30 149. The method of producing a pharmaceutical composition comprising admixing at least one compound according to any one of claims 1 to 86 and a pharmaceutically acceptable carrier or excipient.